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Abstract. Understanding of apoptosis or programmed cell death has provided the basis for novel therapeutics
that has resulted in rationally designed anticancer strategies. Recently, inducers of apoptosis have been used
in cancer therapy. In this work, we describe the role of chiral phthalimides functionalized with piperazines as
potential apoptotic inducers. The listed twenty phthalimides were assessed for their in vitro apoptotic activity
against testicular germ cells. All phthalimides showed a significant apoptotic response (∼39 to ∼68%). TUNEL
assay and acridine orange fluorescence staining were carried out to investigate the molecular mechanisms
responsible for the cell death. Phthalimides exhibited substantial apoptotic induction following the intrinsic
pathway mechanism. Studies advocated that the apoptotic induction was mediated through caspase-9, caspase-
3, JNK MAP kinase and tumor suppressor p53, which was accompanied by DNA fragmentation and nuclear
condensation. Besides, the best five phthalimides regarding apoptotic action were evaluated for in vitro cyto-
toxic effects against CAL-72 and MCF-7 cancer cell lines. Compounds showed efficient killing of cancer cells.
This discovery of functionalized phthalimides as apoptotic inducers would be highly valuable in understanding
the mechanism of apoptosis at the molecular level and opens up new possibilities for therapeutic strategies.
Keywords. Phthalimides; apoptosis; molecular docking; aryl piperazine; cancer cells.
1. Introduction
Apoptosis or programmed cell death is an energy
demanding obligatory process that involves the mor-
phological alteration of tissues, DNA degeneration and
cellular reduction.1 5 Apoptosis is highly helpful for the
organisms to eliminate the unwanted and unnecessary
∗For correspondence
cells viz. senescent, damaged, genetically mutated, or
virus-infected cells. In particular, it is important for
controlling the unlimited cell proliferation that charac-
terizes cancer, which is often a lethal disease.6 10 Cas-
pases, a family of intracellular cysteine proteases play
a significant role in the cellular processes of apoptosis,
inflammation and necrosis.4,11 Two major pathways,
namely extrinsic and intrinsic, have been identified as
possible mechanistic processes of apoptosis.12 Several
mediators such as TNF-α (tumor necrosis factor), Fas
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ligand (FasL), chemotherapy, radiation, etc., are potent
inducers of apoptosis. A mechanistic view of apopto-
sis involves a cascade of initiator and effector caspases
that are activated sequentially. The initiator caspases (2,
8, 9, and 10) are located on the upstream of the signal-
ing cascade. However, executioner caspases (3, 6, and
7) are positioned on the horizon of the cascade. Cas-
pase 3 handles the splitting of many substrates such
as polyADP ribose polymerase (PARP), a DNA repair
enzyme that leads to an unavoidable cell death.13,14
Besides, caspase 3 induces the cleavage of inhibitors
of caspase-activated DNAses (ICAD) and ultimately
cleaves DNA. The activation of caspase 3 following
mitochondrial pathways is considered as a critical tool
for the development of anticancer drug-induced apop-
tosis. Mitogen-activated protein kinases (MAPKs) like
JNK, p38, ERK respond to external stress and drugs.
MAPKs handle the phosphorylation of the immediate
early transcription factor for their respective genes like
c-Jun and c-Fos.15
There is an urgent need for new proapoptotic thera-
peutic agents with novel modes of action, to broaden
the scope of treatment and to overcome emerging drug
resistance. Numerous cytotoxic molecules either natu-
ral or synthetic have been developed to target apoptotic
cell death, an approach considered as crucial for the
future development of anticancer agents.16 20 In recent
years, several piperazine-based molecules have been
reported to possess strong apoptotic activity on cancer-
ous cells.21 28 Piperazine based small amides such as
AK301 (I), have been stated to induce mitotic arrest
and to increase ligand-dependent apoptosis in HT29
human colon cancer cells (ED50: 115 nM).21 Also,
piperazine based alkyl compounds have been reported
to cause apoptosis by inducing RhoB expression via
ROS-mediated cAbl/p38 MAPK signaling.22 She and
co-workers identified few piperazine derivatives, which
potently induce caspase-dependent apoptosis in can-
cer cells.23 Benzothiazole-phthalimide (II) was identi-
fied as an apoptotic inducer to cancer cell lines fol-
lowing caspase-dependent and independent pathways.17
Thalidomide (III)29 possessing isoindoline skeleton is
one of the most explored phthalimide molecules espe-
cially as an antiangiogenic agent.30,31 Moreover, some
reports advocate thalidomide and its derivatives as
potential anti-cancer agents.32,33 Shiheido et al., demon-
strated TC11 (IV) as an inducer of caspases 3, 8 and
PARP.34 Apoptotic inducers attain much attention due
to their potential role in cancer chemotherapy.35,36
Hence, the discovery of apoptotic inducers is one
of the natural choices to secure potential anticancer
agents. To achieve effective new molecules, herein we
present new phthalimides of chemical diversity, which
have been designed by taking into account the vital role
of I-V as anticancer agents (Figure 1). New phthalim-
ides (3a-t) possessing piperazines were prepared and
tested for their in vitro apoptotic activity on testicu-
lar germ cells of goat (Capra hircus) as well as for
their cell viability. The screening advocated phthalim-
ide 3j as the most potential apoptotic inducer following
the intrinsic pathway mechanism. The apoptotic induc-
tion was mediated through caspase-9, caspase-3, JNK
MAP kinase and tumour suppressor p53, which was
accompanied by DNA fragmentation and nuclear con-
densation. To the best of our knowledge, this is the first
study on phthalimides functionalized with arylpiper-
azines as apoptotic inducers, particularly on a domestic
animal.
Figure 1. Structure of compounds having apoptotic and anticancer activity.
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2. Materials and Methods
2.1 Synthesis and characterization of the
phthalimides
2.1a Reagents, equipment and other general issues:
Chemicals and solvents used in the experiment were
commercially available and used as received. All N -
substituted piperazine derivatives were purchased from
Sigma-Aldrich, USA. Homogeneity/purity of all the
products was assayed by thin-layer chromatography
(TLC) on alumina-coated plates (Merck). Product sam-
ples in chloroform (CHCl3) were loaded on TLC plates
and developed in ethylacetate/petroleum ether (1:1,
v/v). When slight impurities were detected by iodine
vapour/UV light visualization, compounds were fur-
ther purified by chromatography on silica gel columns
(100–200 mesh size, CDH). Melting points were deter-
mined on a Büchi M-560 melting point apparatus.
Infrared (IR) spectra were recorded in KBr pellets using
a Perkin-Elmer Fourier Transform-IR spectrometer
(Spectrum RXI-Mid IR), whereas 1H and 13C nuclear
magnetic resonance (NMR) spectra were recorded in
CDCl3 medium on a JNM ECX-400P (JEOL, USA)
spectrometer with tetramethylsilane (TMS) as internal
reference. Absorption frequencies (ν) are expressed in
cm−1, chemical shifts in ppm (δ-scale) and coupling
constants (J ) in Hz. Splitting patterns are described
as singlet (s), doublet (d), triplet (t), quartet (q) and
multiplet (m). High-resolution EI-mass spectra were
performed with a resolution of 10,000 on KRATOS
MS50TC, University of Leuven (KU Leuven), Celestij-
nenlaan 200F, 3001 Leuven, Belgium. The optical rota-
tion of all phthalimides was measured using Autopol III
Polarimeter, Rudolf research analytical. Fluorescence
studies were made by using Fluorescence microscope
(Olympus, Japan) using 500–525 nm filters.
2.1b General procedure for synthesis of phthalimides
(3a-t): To the solution of N -phthaloyl-L-amino acid
(0.4 mmol) in dichloromethane (20 mL), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride, EDC·
HCl (0.6 mmol) and triethylamine, TEA (1.6 mmol)
were added and the contents were stirred at 0◦C for
15 min to secure homogenous reaction mixture. Sub-
sequently, HOBt (0.6 mmol) was added to the reaction
mixture and stirring was continued for another 15 min at
the same temperature. N-substituted piperazine deriva-
tive (0.48 mmol) was added and reaction mixture was
stirred for 24 h at room temperature. The solvent was
evaporated under reduced pressure and the reaction
contents were extracted with ethylacetate and water.
The organic layer was collected separately, concentrated
under reduced pressure and purified by column chro-
matography (ethylacetate/petroleum ether, 4:6). Phthal-
imides (3a, 3e, 3g, 3i and 3m) have been previously
prepared by our team and their structural aspects were
investigated for nonlinear optical property.37 All the
compounds were characterized by spectroscopic tools
and the corresponding spectroscopic data are described
in supporting information.
2.1b1 (S)-2-(1-(4-(4-bromobenzyl)piperazin-1-yl)-1-
oxo-3-phenyl propan-2-yl)isoindoline-1,3-dione (3b):
The title compound was obtained as white solid having
yield 72%; M.p.: 125–127◦C; [α]D26 −150.6 (c = 0.2
in ethylacetate); FTIR (KBr) νmax (cm−1): 3026, 2882,
2826, 1712 (C=O, imide), 1663 (C=O, amide), 1426,
1384, 996, 719; 1H NMR (400 MHz, CDCl3) δ 7.76-
7.73 (m, 2H, H-4, H-7), 7.69-7.66 (m, 2H, H-5, H-6),
7.40 (d, J = 8.05 Hz, 2H, H-3′′′), 7.17-7.11 (m, 7H,
Ar-H), 5.22 (dd, J = 5.86, 9.32 Hz, 1H, H-2′), 3.79-
3.41 (m, 8H, H-3′, H-1′′′′, H-2′′, H-6′′), 2.38 (m, 4H,
H-3′′, H-5′′) ppm; 13C NMR (100 MHz, CDCl3): δ
167.59 (C=O), 166.72 (C=O), 136.90, 134.15, 131.49,
131.29, 130.82, 129.06, 128.51, 126.85, 123.43, 61.71,
60.34, 52.40, 44.83, 42.00, 35.03 ppm; HRMS m/z
calculated [M]+ for C28H26BrN3O+3 531.1158; found:
531.1150.
2.1b2 (S)-2-(1-(4-(4-bromobenzyl)piperazin-1-yl)-3-
methyl-1-oxobutan-2-yl)isoindoline-1,3-dione (3c): The
title compound was obtained as white solid having
yield 62%; M.p.: 108–110◦C; [α]D26 −79.3 (c = 0.2
in ethylacetate); FTIR (KBr) νmax (cm−1) 2963, 2927,
1716 (C=O, imide), 1654 (C=O, amide), 1466, 1382,
1070, 720; 1H NMR (400 MHz, CDCl3) δ 7.78-7.76
(m, 2H, H-4, H-7), 7.70-7.65 (m, 2H, H-5, H-6),
7.35 (d, J = 8.05 Hz, 2H, H-3′′′), 7.12-7.10 (m, 2H,
H-2′′′), 4.55 (d, J = 10.25 Hz, 1H, H-2’), 3.61 (s,
2H, H-1′′′′) 3.50-3.41 (m, 4H, H-2′′, H-6′′), 3.03-3.00
(m, 1H, H-3’), 2.42-2.22 (m, 4H, H-3′′, H-5′′), 0.97
(d, J = 6.59 Hz, 3H, H-4’), 0.80 (d, J = 6.59 Hz,
3H, H-4’) ppm; 13C NMR (100 MHz, CDCl3): δ
167.73 (C=O), 166.65 (C=O), 134.30, 131.57, 131.30,
130.94, 130.90, 123.56, 61.67, 56.14, 52.82, 52.47,
29.66, 27.52, 20.53, 19.13 ppm; HRMS m/z calculated
[M]+ for C24H26BrN3O+3 483.1158; found: 483.1126.
2.1b3 2-((2S,3S)-1-(4-(4-bromobenzyl)piperazin-1-yl)-
3-methyl-1-oxopentan-2-yl)isoindoline-1,3-dione (3d):
The title compound was obtained as white solid having
yield 69%; M.p.: 101–103◦C; [α]D28 −13.7 (c = 0.2 in
ethylacetate); FTIR (KBr) νmax (cm−1) 2965, 2929,
1713 (C=O, imide), 1657 (C=O, amide), 1434, 1383,
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1072, 722; 1H NMR (400 MHz, CDCl3) δ 7.78-7.76
(m, 2H, H-4, H-7), 7.68-7.63 (m, 2H, H-5, H-6), 7.36
(d, J = 7.32 Hz, 2H, H-3′′′), 7.13 (s, 2H, H-2′′), 4.67
(d, J = 10.25 Hz, 1H, H-2′), 3.57-3.41 (m, 6H, H-1′′′′,
H-2′′, H-6′′), 2.86-2.79 (m, 1H, H-3′), 2.35 (m, 4H,
H-3′′, H-5′′), 1.33–1.41 (m, 1H, H-4′), 1.04–0.97 (m,
1H, H-4′), 0.92 (d, J = 5.86 Hz, 3H, H-6′), 0.79 (t,
J = 7.32 Hz, 3H, H-5′) ppm; 13C NMR (100 MHz,
CDCl3) δ 167.82 (C=O), 166.98 (C=O), 134.27,
131.63, 131.34, 131.27, 131.08, 131.01, 123.53, 61.64,
54.88, 52.87, 33.71, 33.04, 25.29, 16.47, 15.14, 11.40,
10.58 ppm; HRMS m/z calculated [M]+ for C25H28
BrN3O
+
3 497.1314; found 497.1293.
2.1b4 (S)-2-(1-(4-(4-fluorobenzyl)piperazin-1-yl)-1-oxo-
3-phenyl propan-2-yl)isoindoline-1,3-dione (3f): The
title compound was obtained as white solid having
yield 65%; M.p.: 131–133◦C; [α]D27 −137.3 (c = 0.2
in ethylacetate); FTIR (KBr) νmax (cm−1) 3058, 2916,
1713 (C=O, imide), 1661 (C=O, amide), 1429, 1384,
1225, 720; 1H NMR (400 MHz, CDCl3)δ 7.71-7.69
(m, 2H, H-4, H-7), 7.63-7.61 (m, 2H, H-5, H-6), 7.21-
7.19 (m, 2H, H-3′′′), 7.14-7.08 (m, 5H, Ar), 6.92 (t,
J = 8.79 Hz, 2H, H-2′′′), 5.17 (dd, J = 9.52, 6.59 Hz,
1H, H-2′), 3.54-3.40 (m, 8H, H-1′′′′, H-3′, H-2′′, H-6′′),
2.60-2.20 (m, 4H, H-3′′, H-5′′) ppm; 13C NMR (100
MHz, CDCl3): δ 167.62 (C=O), 166.81 (C=O), 162.42
(d, 1JC−F = 251.12 Hz), 134.22, 131.31, 129.11,
128.56, 126.91, 123.48, 115.42 (d, 2JC−F = 20.13 Hz),
61.46, 52.38, 52.21, 35.07, 29.65 ppm; HRMS m/z
calculated [M]+ for C28H26FN3O+3 471.1958; found
471.1969.
2.1b5 2-((2S,3S)-1-(4-(4-fluorobenzyl)piperazin-1-yl)-
3-methyl-1-oxopentan-2-yl)isoindoline-1,3-dione (3h):
The title compound was obtained as white solid having
yield: 69%; M.p.: 111–113◦C; [α]D25 −17.3 (c = 0.2
in ethylacetate); FTIR (KBr) νmax (cm−1) 2929, 2870,
1716 (C=O, imide), 1668 (C=O, amide), 1590, 1471,
1110, 721 ppm; 1H NMR (400 MHz, CDCl3)δ 7.82-
7.80 (m, 2H, H-4, H-7), 7.72-7.69 (m, 2H, H-5, H-6),
7.20-7.17 (m, 2H, H-3′′′), 6.99 (m, 2H, H-4′′′), 4.72
(d, J = 10.68 Hz, 1H, H-2′), 3.62-3.52 (m, 4H, H-2′′,
H-6′′), 3.38 (s, 2H, H-1′′′′), 2.99-2.88 (m, 1H, H-3′),
2.37-2.25 (m, 4H, H-3′′, H-5′′), 1.35–1.39 (m, 1H,
H-3′), 1.04-1.00 (m, 1H, ), 0.96 (d, J = 6.87 Hz, 3H,
H-6′), 0.83 (t, J = 7.33 Hz, 3H, H-5′) ppm; 13C NMR
(100 MHz, CDCl3) δ 167.83 (C=O), 166.88 (C=O),
162.02 (d, 1JC−F = 244.41 Hz), 134.19, 133.22,
131.39, 130.46 (d, 3JC−F = 7.67 Hz), 123.49, 115.07
(d, 2JC−F = 21.09 Hz), 61.84, 54.90, 52.67, 45.74,
42.26, 33.09, 25.28, 16.50, 10.60 ppm. HRMS m/z
calculated [M]+ for C25H28FN3O+3 437.2115; found
437.2116.
2.1b6 (S)-2-(1-oxo-3-phenyl-1-(4-(4-(trifluoromethyl)
benzyl) piperazin-1-yl)propan-2-yl) isoindoline-1,3-dione
(3j): The title compound was obtained as white solid
having yield 72%; M.p.: 112–113◦C; [α]D26 −141.3
(c = 0.2 in ethylacetate); FTIR (KBr) νmax (cm−1) =
3060, 2928, 1712 (C=O, imide), 1686 (C=O, amide),
1385, 1329, 1126, 720. 1H NMR (400 MHz, CDCl3)
δ 7.76-7.73 (m, 2H, H-4, H-7), 7.68-7.66 (m, 2H, H-
5, H-6), 7.54 (d, J = 7.32 Hz, 2H, H-3′′′), 7.42–
7.48 (m, 2H, H-2′′′), 7.16–7.12 (m, 5H, Ar), 5.22 (dd,
J = 5.86, 9.52 Hz, 1H, H-2′), 3.59-3.44 (m, 8H,
H-1′′′′, H-3′, H-2′′, H-6′′), 2.43 (m, 4H, H-3′′, H-5′′)
ppm; 13C NMR (100 MHz, CDCl3) δ 167.61 (C=O),
166.80 (C=O), 136.86, 134.20, 131.29, 129.09, 128.55,
126.91, 125.44, 123.47, 61.69, 52.51, 35.07, 31.87,
29.64, 22.6, 14.07 ppm. HRMS m/z calculated [M]+ for
C29H26F3N3O
+
3 521.1926; found 521.1926.
2.1b7 (S)-2-(3-methyl-1-oxo-1-(4-(4-(trifluoromethyl)
benzyl) piperazin-1-yl)butan-2-yl)isoindoline-1,3-dione
(3k): The title compound was obtained as white solid
having yield 63%; M.p.: 102–105◦C; [α]D25 −78.0 (c =
0.2 in ethylacetate). FTIR (KBr) νmax (cm−1) 2964,
2925, 1715 (C=O, imide), 1662 (C=O, amide), 1467,
1383, 1326, 1126, 720. 1H NMR (400 MHz, CDCl3)
δ 7.83-7.80 (m, 2H, H-4, H-7), 7.74-7.69 (m, 2H, H-
6, H-6), 7.51 (d, J = 8.05 Hz, 2H, H-3′′′), 7.36 (d,
J = 8.05 Hz, 2H, H-2′′′), 4.61 (d, J = 10.25 Hz,
1H, H-2′), 3.65-3.46 (m, 4H, H-2′′, H-6′′), 3.47 (s, 2H,
H-1′′′′), 3.09-3.04 (m, 1H, H-3′), 2.37-2.21 (m, 4H,
H-3′′. H-5′′), 1.02 (d, J = 6.59 Hz, 3H, H-4′), 0.86
(d, J = 6.59 Hz, 3H, H-4′) ppm. 13C NMR (100
MHz, CDCl3) δ 167.74 (C=O), 166.64 (C=O), 134.28,
131.33, 129.21, 125.27, 123.55, 65.83, 61.99, 61.38,
56.16, 53.05, 52.74, 45.45, 42.13, 30.11, 27.55, 20.55,
19.13, 15.25, 14.07 ppm. HRMS m/z calculated [M]+
for C25H26F3N3O
+
3 473.1926; found 473.1944.
2.1b8 2-((2S,3S)-3-methyl-1-oxo-1-(4-(4-(trifluoromethyl)
benzyl)piperazin-1-yl)pentan-2-yl)isoindoline-1,3-dione
(3l): The title compound was obtained as white solid
having yield 59%; M.p.: 116–118◦C; [α]D25 −9.37
(c = 0.2 in ethylacetate); FTIR (KBr) νmax (cm−1) =
2966, 2928, 1718 (C=O, imide), 1638 (C=O, amide),
1458, 1327, 1123, 721; 1H NMR (400 MHz, CDCl3)δ
7.82–7.80 (m, 2H, H-4, H-7), 7.72–7.70 (m, 2H), 7.51
(m, 2H, H-3′′′), 7.37 (m, 2H, H-2′′′), 4.73 (d, J =
10.98 Hz, 1H, H-2′), 3.64-3.55 (m, 2H, H-2′′, H-6′′),
3.49 (s, 2H, H-1′′′′), 2.91 (m, 1H, H-3′), 2.38-2.29 (m,
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4H, H-3′′, H-5′′), 1.39-1.34 (m, 1H, H-4′), 1.07-1.00
(m, 1H, H-4′), 0.97 (d, J = 6.59 Hz, 3H, H-6′), 0.84
(dd, J = 7.32, 13.91 Hz, 3H, H-5′) ppm; 13C NMR
(100 MHz, CDCl3) δ 167.82 (C=O), 166.92 (C=O),
134.22, 131.38, 131.30, 129.15, 125.26, 124.09 (q,
1JC−F = 272.20 Hz), 123.50, 61.98, 54.91, 53.09,
52.73, 45.63, 42.22, 33.74, 33.09, 27.03, 25.28, 16.48,
15.13, 11.39, 10.58, ppm; HRMS m/z calculated [M]+
for C26H28F3N3O
+
3 487.2083; found 487.2060.
2.1b9 (S)-2-(1-(4-(4-(tert-butyl)benzyl)piperazin-1-yl)-
1-oxo-3-phenylpropan-2-yl)isoindoline-1,3-dione (3n):
The title compound was obtained as white solid having
yield 71%; M.p.: 138–140◦C; [α]D27 −154.6 (c = 0.2
in ethylacetate); FTIR (KBr) νmax (cm−1) 3060, 2962,
1714 (C=O, imide), 1663 (C=O, amide), 1429, 1384,
1102, 716; 1H NMR (400 MHz, CDCl3) δ 7.76–7.73
(m, 2H, H-4, H-7), 7.68-7.65 (m, 2H, H-5, H-6), 7.31
(d, J = 8.79 Hz, 2H, H-3′′′), 7.20 (d, J = 7.32 Hz,
2H, H-2′′′), 7.17-7.12 (m, 5H, Ar-H), 5.22 (dd, J =
9.52, 5.86 Hz, 1H, H-2′), 3.63-3.42 (m, 8H, H-1′′′′,
H-3′, H-2′′, H-6′′), 2.43-2.30 (m, 4H), 1.28 (s, 9H,
H-6′′′) ppm. 13C NMR (100 MHz, CDCl3) δ 167.61
(C=O), 166.68 (C=O), 136.97, 134.10, 131.34, 129.05,
128.91, 128.49, 126.81, 125.23, 123.40, 62.19, 52.44,
35.01, 34.43, 31.29 ppm. HRMS m/z calculated [M]+
for C32H35N3O
+
3 509.2678; found 509.2702.
2.1b10 (S)-2-(1-(4-(4-(tert-butyl)benzyl)piperazin-1-ył)-
3-methyl-1-oxobutan-2-yl)isoindoline-1,3-dione (3o):
The title compound was obtained as white solid having
yield 68%; M.p.: 135–137◦C; [α]D26 −79 (c = 0.2
in ethylacetate); FTIR (KBr) νmax (cm−1) 3008, 2964,
2871, 1714 (C=O, imide), 1660 (C=O, amide), 1468,
1382, 1071, 720; 1H NMR (400 MHz, CDCl3) δ 7.82-
7.81 (m, 2H, H-4, H-7), 7.73-7.71 (m, 2H, H-5, H-6),
7.30 (d, J = 8.05 Hz, 2H, H-3′′′), 7.20 (d, J = 6.59
Hz, 2H, H-2′′′), 4.59 (d, J = 10.25 Hz, 1H, H-2′),
3.72-3.50 (m, 6H, H-1′′′′, H-2′′, H-6′′), 3.08-3.01 (m,
1H, H-3′), 2.56-2.39 (m, 4H, H-3′′, H-5′′), 1.27 (s, 9H,
H-6′′′), 1.01 (d, J = 6.59 Hz, 3H, H-4′), 0.85 (d, J =
6.59 Hz, 3H, H-4′) ppm; 13C NMR (100 MHz, CDCl3)
δ 167.95 (C=O), 166.64 (C=O), 134.32, 131.28,
129.76, 125.58, 123.59, 61.94, 56.07, 34.68, 31.27,
27.49, 20.53, 18.98 ppm; HRMS m/z calculated [M]+
for C28H35N3O
+
3 461.2678; found 461.2659.
2.1b11 2-((2S,3S)-1-(4-(4-(tert-butyl)benzyl)piperazin-
1-yl)-3-methyl-1-oxopentan-2-yl) isoindoline-1,3-dione
(3p): The title compound was obtained as white solid
having yield 80%; M.p.: 102–104◦C; [α]D27 −10.7
(c = 0.2 in ethylacetate); FTIR (KBr) νmax (cm−1)
2963, 2875, 1715 (C=O, imide), 1660 (C=O, amide),
1463, 1381, 1073, 721; 1H NMR (400 MHz, CDCl3) δ
7.78–7.76 (m, 2H, H-4, H-7), 7.67-7.65 (m, 2H, H-5,
H-6), 7.25 (d, J = 8.05 Hz, 2H, H-3′′′), 7.13 (d, J =
8.05 Hz, 2H, H-2′′′), 4.68 (d, J = 10.25 Hz, 1H, H-2′),
3.61-3.45 (m, 4H, H-2′′, H-6′′), 3.39 (s, 2H, H-1′′′′),
2.90-2.78 (m, 1H, H-3′), 2.40-2.24 (m, 4H, H-3′′,
H-5′′), 1.35–1.28 (m, 1H, H-4′), 1.23 (s, 9H, H-6′′′′),
1.01–0.95 (m, 1H, H-4′), 0.93 (d, J = 6.59 Hz, 3H,
H-5′), 0.81 (dd, J = 6.95, 7.32 Hz, 3H, H-5′) ppm;
13C NMR (100 MHz, CDCl3) δ 167.83 (C=O), 166.80
(C=O), 134.21, 131.36, 129.01, 125.29, 123.51, 62.17,
54.88, 52.98, 52.98, 45.43, 41.64, 34.46, 33.07, 31.30,
25.27, 16.49, 10.60 ppm; HRMS m/z calculated [M]+
for C29H37N3O
+
3 475.2835; found 475.2885.
2.1b12 (S)-2-(4-methyl-1-oxo-1-(4-phenethylpiperazin-
1-yl)pentan-2-yl)isoindoline-1,3-dione (3q): The title
compound was obtained as yellow oil having yield
80%; [α]D27 −16.2 (c = 0.2 in ethylacetate); FTIR
(KBr) νmax (cm−1) = 2958, 2928, 1715 (C=O, imide),
1670 (C=O, amide), 1438, 1381, 1197, 720; 1H NMR
(400 MHz, CDCl3) δ 7.85–7.82 (m, 2H, H-4, H-7),
7.75–7.71 (m, 2H, H-5, H-6), 7.30–7.16 (m, 5H, H-1′′′-
H-4′′′), 5.10 (dd, J = 11.45, 4.58 Hz, 1H, H-2′), 3.84-
3.65 (m, 4H, H-2′′, H-6′′), 2.93 (br s, 4H, H-1′′′′, H-2′′′′),
2.87-2.78 (m, 4H, H-3′′, H-5′′), 2.60-2.55 (m, 1H,
H-3′), 1.67–1.62 (m, 1H, H-3′), 1.55-1.52 (m, 1H,
H-4′), 0.95 (d, J = 1.83 Hz, 3H, H-5′), 0.93 (d,
J = 2.29 Hz, 3H, H-5′) ppm. 13C NMR (100 MHz,
CDCl3) δ 168.18 (C=O), 167.70 (C=O), 139.75,
134.09, 131.65, 128.60, 128.39, 126.13, 123.41, 60.00,
53.10, 52.61, 49.96, 45.44, 42.35, 37.19, 29.64, 25.21,
23.10, 21.22 ppm; HRMS m/z calculated [M]+ for
C26H31N3O
+
3 433.2365; found 433.2194.
2.1b13 (S)-2-(1-oxo-1-(4-phenethylpiperazin-1-yl)-3-
phenylpropan-2-yl)isoindoline-1,3-dione (3r): The title
compound was obtained as yellow solid having yield
72%; M.p.: 101-103◦C; [α]D27 −160.7 (c = 0.2 in
ethylacetate); FTIR (KBr) νmax (cm−1) 3029, 2928,
2373, 1715 (C=O, imide), 1675 (C=O, amide), 1438,
1382, 1198, 720; 1H NMR (400 MHz, CDCl3) δ
7.80-7.76 (m, 2H, H-4, H-7), 7.73–7.70 (m, 2H, H-
5, H-6), 7.31-7.13 (m, 10H, Ar), 5.21 (t, J = 8.05
Hz, 1H, H-2′), 3.65-3.52 (m, 6H, H-3′, H-2′′, H-
6′′), 3.00-2.97 (m, 8H, H-1′′′′, H-2′′′′, H-3′′, H-5′′)
ppm; 13C NMR (100 MHz, CDCl3) δ 167.63 (C=O),
167.18 (C=O), 136.53, 135.75, 134.45, 131.17, 129.24,
129.02, 128.73, 128.56, 123.37, 127.20, 123.62, 58.44,
52.06, 51.51, 42.70, 39.50, 35.20, 39.29 ppm, HRMS
m/z calculated [M]+ for C29H29N3O+3 467.2209; found
467.2204.
1250 Anil K Singh et al.
2.1b14 (S)-2-(3-methyl-1-oxo-1-(4-phenethylpiperazin-
1-yl)butan-2-yl)isoindoline-1,3-dione (3s): The title
compound was obtained as yellow oil having yield
61%; [α]D27 −92 (c = 0.2 in ethylacetate); FTIR (KBr)
νmax (cm−1) 3012, 2965, 2874, 1715 (C=O, imide),
1662 (C=O, amide), 1455, 1383, 1071, 721; 1H NMR
(400 MHz, CDCl3) δ 7.84-7.82 (m, 2H, H-4, H-7),
7.72-7.70 (m, 2H, H-5, H-6), 7.22-7.12 (m, 5H, Ar-
H), 4.63 (d, J = 10.68 Hz, 1H, H-2′), 3.66-3.53 (m,
4H, H-2′′, H-6′′), 3.11-3.03 (m, 1H, H-3′), 2.75-2.71
(m, 2H, H-1′′′′), 2.55-2.51 (m, 2H, H-2′′′′), 2.46-2.35
(m, 4H, H-3′′, H-5′′), 1.03 (d, J = 6.10 Hz, 3H, H-
4′), 0.86 (d, J = 6.59 Hz, 3H, H-4′) ppm; 13C NMR
(100 MHz, CDCl3) δ 167.77 (C=O), 166.71 (C=O),
134.33, 131.29, 128.59, 128.52, 126.39, 123.58,
59.59, 56.14, 52.91, 52.43, 45.05, 41.47, 32.45, 27.48,
20.49, 19.14 ppm HRMS m/z calculated [M]+ for
C25H29N3O
+
3 419.2209; found 419.2215.
2.1b15 2-((2S,3S)-3-methyl-1-oxo-1-(4-phenethylpi-
perazin-1-yl)pentan-2-yl)isoindoline-1,3-dione (3t): The
title compound was obtained as yellow oil having yield
67%; [α]D27−10.7 (c = 0.2 in ethylacetate); FTIR
(KBr) νmax (cm−1) = 2965, 2933, 1715 (C=O, imide),
1652 (C=O, amide), 1456, 1382, 1073, 721; 1H NMR
(400 MHz, CDCl3) δ 7.84-7.78 (m, 2H, H-4, H-7),
7.72-7.67 (m, 2H, H-5, H-6), 7.25-7.12 (m, 5H, Ar-H),
4.75 (d, J = 10.68 Hz, 1H, H-2′), 3.66-3.54 (m, 4H,
H-2′′, H-6′′), 2.96-2.90 (m, 1H, H-3′), 2.75-2.70 (m,
2H, H-1′′′′), 2.56-2.52 (m, 2H, H-2′′′′), 2.44-2.35 (m,
4H, H-3′′, H-5′′), 1.41-1.32 (m, 1H, H-4′), 1.10-1.02
(m, 1H, H-4′), 0.97 (d, J = 6.59 Hz, 3H, H-6′), 0.83
(dd, J = 6.87, 13.73 Hz, 3H, H-5′) ppm; 13C NMR
(100 MHz, CDCl3) δ 167.87 (C=O), 167.00 (C=O),
134.26, 131.37, 128.60, 128.51, 126.37, 123.53, 59.58,
54.89, 53.00, 52.24, 44.86, 41.28, 33.02, 25.31, 20.87,
16.45, 10.55 ppm; HRMS m/z calculated [M]+ for
C26H31N3O
+
3 433.2365; found 433.2365.
2.2 Biological Experiments
2.2a Collection of materials: Goat (Capra hircus)
testes (n = 10) were procured from the slaughter
houses around Kurukshetra (26◦6′ N, 76◦5′ E), India
and brought to laboratory in normal saline at 4◦C.
Subsequently, the testes were decapsulated, cut into
smaller pieces (Approximately 1 mm3) and processed
for testicular tissue culture in vitro.
2.2b Testicular tissue culture in vitro: The testicular
tissues (1 mm3) were washed three times with
phosphate buffer saline (PBS) and then cultured in
Dulbecco’s modified Eagle’s Medium (DMEM) supple-
mented with antibiotics (200-unit having concentration
of penicillin 100 IU/mL and streptomycin 100 IU/mL)
in CO2 incubator (5% CO2, 95% humidity, 38◦C). The
testicular tissues were incubated with 10 μM of each
tested compound in DMSO. Thereafter, the harvest-
ing of testicular tissues was performed after 6 h of cul-
ture duration. The harvested testicular tissue cultures
were washed with PBS and fixed in alcoholic Bouin’s
fixative for 24 h. Following dehydration in series of
ethanol grades, the testicular tissues were cleared in
xylene and embedded in paraffin wax. The paraffin
blocks were prepared and sections were cut at 5–7 μm
thickness. These sections were deparaffinised in xylene,
stained with haematoxylin and eosin, and then mounted
in DPX. The specific sections were observed under
microscope (Olympus, Japan).38,39
2.2c Testicular germ cell isolation and treatment with
3j: A two-step enzymatic method was used to isolate
the germ cells from the goat testis with a few modifi-
cations as described previously.14,15 Briefly, the excised
testis was rinsed in 10 mL of Hank’s balanced salt solu-
tion (HBSS) and the tunica albuginea along with other
visible connective tissues were removed. The seminifer-
ous tubule mass (4–5 g) was transferred to 10 mL fresh
HBSS containing 0.25 mg/mL collagenase and kept for
15 minutes at 37◦C with constant shaking. The dis-
persed seminiferous tubules were allowed to sediment
and washed thrice in the fresh HBSS. The supernatant
was decanted each time, which largely removed con-
tamination from the interstitial and blood cells. The
isolated tubules were washed and subjected to trypsin
(1.25 mg/mL) and DNase I (50 μg/mL) treatment for
10–15 min with shaking. The resultant crude cell sus-
pension was filtered through 100 μm and 43 μm mesh
filter which removed clumped/clustered cells, washed
following centrifugation at 500 g for 5 min at room
temperature and re-suspended in DMEM containing
100 μg/mL streptomycin sulphate and 100 IU/mL peni-
cillin. Viability of the final cell preparation was >95%
as determined by trypan blue exclusion method. The
isolated testicular germ cells (5 × 106 cells/mL/tube)
were incubated for 6 h at 38◦C with or without 3j in
DMEM. Phthalimide 3j exhibited substantial apoptotic
induction (∼68%), hence chosen for further investiga-
tion. Incubations with 3j were made at final concen-
trations of 0, 2, 5, 10 and 20 μM. The treated cells
were washed in PBS and stored at −20◦C till further
use. Approximately, 80% cells were viable in 10 μM
3j exposed group, however the viability was ∼65% in
20 μM 3j treated group. Therefore, 10 μM was used in
further studies and treatments.
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2.2d In Situ End Labelling (TUNEL Assay): Testicu-
lar germ cells were harvested from the mature goat
(Capra hircus) testes and cultured in DMEM medium
supplemented with antibiotics (200 unit penicillin
100 IU/mL and streptomycin 100 IU/mL) in CO2 incu-
bator (5% CO2, 95% humidity, 38◦C) for 6 h culture
duration. The cells were plated at a density of 105 cells/mL
and incubated with 10 μM of each tested compound in
DMSO. Then the cell apoptosis was assayed by TUNEL
(Terminal deoxynucleotidyl-transferase d-UTP medi-
ated nick end labelling). TUNEL was carried out as per
manufacturer’s (R&D Systems, Inc., Minneapolis, MN,
USA) instructions. Briefly, the testicular germ cells
were smeared on poly-L-Lysine coated slides and fixed
in 4% formaldehyde. Cells were treated with cytonin
for 10 min followed by quenching with H2O2. Biotiny-
lated nucleotides were incorporated in to 3’-OH ends
of the DNA fragments by TdT, and detected by using
streptavidin horseradish peroxidase (HRP). The colour
was developed by diaminobenzidine (DAB) solution
and counterstained with methyl green. TUNEL positive
cells were examined under a microscope.40,41
2.2e Acridine orange fluorescence: Testicular germ
cells were harvested from the mature goat (Capra hir-
cus) testes and cultured in DMEM medium supple-
mented with antibiotics (200 unit penicillin 100 IU/mL
and streptomycin 100 IU/mL) in CO2 incubator (5%
CO2, 95% humidity, 38◦C) for 6 h culture duration.
The cells were plated at a density of 105 cells/mL and
incubated with 10 μM of each tested compound in
DMSO. Then the cell apoptosis was assayed by Acri-
dine Orange staining after 6 h of culture duration under
fluorescence microscope (Olympus, Japan) using 500–
525 nm filters. Normal cells were identified by their
intact cell membrane and round nucleus with scanty
chromatin. Cells with bright green condensed nuclei
(intact or fragmented) were interpreted as apoptotic.38
2.2f Lipid peroxidation and antioxidant enzymes
activity: Treated or untreated testicular germ cells were
sonicated for 30 s and divided into two equal parts.
One part was assayed for lipid peroxidation through
the formation of thiobarbituric acid reactive substances
(TBARS) in the reaction mixture as described in
literature.42 The second part was centrifuged at 10000 g
for 5 min and the supernatant was assayed for antiox-
idant enzyme activity. SOD was measured following
the literature procedure.43 Catalase was estimated by
the degradation of hydrogen peroxide (6 mM) as des-
cribed by Aebi.44 GST activity towards 1-chloro-2,4-
dinitrobenzene (CDNB) was measured by the reported
method.45 Protein was estimated by Bradford assay.46,47
2.2g Caspase 3, 8, 9 activities: The activity of cas-
pase 3/8/9 was assayed as per the manufacturer’s pro-
tocol supplied in the caspase colorimetric assay kit
(Biovision, San Diego, CA, USA). Briefly, germ cells
were resuspended in cold lysis buffer and incubated for
10 min. Cell lysates were centrifuged for 2 min at 10000
g at 4◦C. An aliquot of supernatant (100 μg protein/
50 μL) was added to 50 μL of reaction buffer contain-
ing 200 μM of chromogen (Ac-DEVD-pNA/Ac-IETD-
pNA/Ac-LEHD-pNA for caspase 3, 8, 9 respectively),
kept at 37◦C for 2 h and terminated by adding stop
buffer. The change in the absorbance due to the release
of p-nitroanilide (p-NA) was measured at 405 nm using
micro-titre plate reader (BioTek Inc., USA).
2.2h Western blot analysis: Primary antibodies (rabbit
polyclonal) anti-Caspase 9, anti-JNK, c-Jun, PARP and
(mouse monoclonal) anti-Caspase 8, anti-pJNK, anti-
p-c-Jun, anti-p53, anti-β-actin (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) were utilized. Goat anti-
rabbit/mouse-HRP conjugate secondary antibody from
Santa Cruz Biotechnology was procured. Lysates were
prepared and western blotting was carried out following
literature method.15 Briefly, whole cell lysates were pre-
pared in 200 μL lysis buffer containing 20 mM HEPES
(pH 7.4), 2 mM EDTA, 50 mM β-glycerophosphate,
1% Triton X-100, 150 mM NaCl, 10% Glycerol and
protease inhibitor cocktail (Roche, Basel, Switzerland).
β-actin was used to monitor equal loading of protein.
Densitometric analysis was performed with the help of
Image analysis software (Lab Works Image analysis
software 4.0, UVP, Upland, CA, USA).
2.2i RNA isolation and RT-PCR analysis: Total
RNA was isolated using TRI-Reagent (Ambion, TX,
USA). cDNA was synthesized using 2 μg of the total
RNA by omniscript RT kit (Qiagen, Hilden, Ger-
many). 2 μL of the RT reaction was then used for
PCR using the HotStar HiFidelity DNA polymerase
(Qiagen). Primers were procured from Eurofins MWG
Operon (Whitefield, Bangalore, India). The PCR reac-
tions were carried out under the following temperature
profile: (1) denaturation at 95◦C for 15 min; (2) 28–
30 cycles of 95◦C for 30 sec, 60–65◦C for 1 min, 72◦C
for 1 min; (3) a final extension for 10 min at 72◦C. The
sequence, source, annealing temperature, Mg2+ con-
centration, PCR cycles and product size of primers
are shown in Table S2 (Supporting Information). After
amplification, the products were separated on 1.5%
agarose and documented with the help of gel documen-
tation system (UVP, CA, USA). β-actin was used as
an internal control. The analysis of RT-PCR results was
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completed with the aid of Image analysis software (Lab
Works Image analysis software 4.0, UVP, Upland, CA,
USA).
2.2j Cell viability studies using cancer cell lines:
The viability of two cancer cell lines was evaluated
using the five most promising phthalimides in terms
of apoptotic activity (3b, 3f, 3j, 3m & 3p). The dose-
response behaviour was studied and, when applicable,
the IC50 value was estimated. MCF-7 cells (human
breast cancer cell line) and CAL-72 cells (human bone
cancer cell line) were cultured in Roswell Park Memo-
rial Institute-1640 and Minimum Essential Media,
respectively, supplemented with 10% heat-inactivated
fetal bovine serum (Gibco) and 1% antibiotic–
antimycotic 100X solution (containing penicillin, strep-
tomycin and amphotericin B; Gibco). Cells were grown
in a humidified incubator at 37◦C and 5% CO2. The sub-
confluent cells were harvested using a trypsin solution
(Sigma-Aldrich).
To determine the metabolic activity of both cancer
cell lines, cells were plated in 96-well plates, at a dif-
ferent density for each cell line: 10000 cells (MCF-7)
and 5000 cells (CAL-72) per well. Cells were seeded
diluted in 100 μL of culture medium and were allowed
to adhere overnight. Then, after media removal, they
were treated with the compounds under testing at dif-
ferent concentrations: 100 μM, 80 μM, 60 μM, 40 μM,
20 μM, 10 μM, 5 μM, 2.5 μM and 1 μM (final concen-
trations in the wells). For this, a mother solution of each
compound was prepared in DMSO and serial dilutions
with DMSO were made to attain the desired concentra-
tions. At the end, 10 μL of the different solutions were
added to each well together with 990 μL of cell culture
medium. The respective controls were performed with
the adequate 1% (v/v) of DMSO.
The effect of the compounds was evaluated by the
resazurin reduction assay. After cell incubation with
compounds for 48 h, culture medium was removed
replaced with fresh medium containing resazurin at a
concentration of 0.1 mg/mL (Sigma-Aldrich) for 4 h.
Afterwards, aliquots of the cell supernatant were trans-
ferred to 96-well opaque plates and the resorufin fluo-
rescence (λex = 530 nm, λem = 590 nm) was measured
using a microplate reader (Victor3 1420, PerkinElmer).
2.2k Statistical Analysis: Each Figure (for western
blotting and RT-PCR) is a representative of three inde-
pendent experiments with similar results. The error
bars represent standard deviations (SD) of three exper-
iments done in triplicates. Statistical analysis was
performed using Student’s t test and one-way ANOVA
followed by Tukey’s test using SPSS-15. The results
were considered statistically significant at p < 0.05.
2.3 Molecular Docking methodology
In silico docking of 3j into the active sites of caspase
proteins was performed using the Glide (Schrödinger
suite version 9.3) software.48 Initially, the ligand bound
complex crystal structures of seven human caspases
were obtained from protein data bank (RCSB-PDB).49
The ligand and water molecules were removed, and
hydrogen atoms were added to the crystal structure fol-
lowed by all-atom charges. Atom types were assigned.
Protein preparation wizard of Glide was used for energy
minimization and refinement of the structure. The opti-
mized target proteins were taken for docking studies.
The compound 3j was drawn in 2D sketcher.50 Lig-
Prep protocol51 was used for further minimization and
to ensure the correct protonated state for the ligand.
Before docking, experimental ligand binding sites from
crystal structure was obtained to define an active site
in each caspases. The ligand (3j) was docked into the
active sites of each caspase protein using the “extra-
precision” (XP) mode of the Glide cross-docking pro-
gram. Multiple conformers of the ligand (3j) were
docked eventually against each rigid receptor (caspases)
followed by a flexible docking protocol.52 A binding
free energy (Gbind) for each docked pose was further
estimated using Prime MM-GBSA method.53 The com-
plex that had the lowest glide score was refined using
G bind score.
3. Results and Discussion
3.1 Synthesis and characterization of the different
phthalimides
To achieve the designed compounds, the starting mate-
rials N -phthaloyl-L-amino acids (1a-d) were synthe-
sized following the literature procedure.54 N -phthaloyl-
L-amino acids were coupled with arylpiperazines (2a-e)
in the presence of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC·HCl) and hydrox-
ylbenzotriazole (HOBt) as a coupling reagent and
racemization inhibitor, respectively (scheme 1). Tri-
ethylamine (TEA) was employed as a base in the reac-
tion. The composition of new phthalimides was con-
firmed by spectroscopic techniques i.e., NMR (1H and
13C), IR and HRMS. In NMR spectra, the chemical
shifts of various protons and carbons were assigned
using DEPT-45, 90, 135 and HETCOR experiments.
The coupling between the protons was assigned with
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Scheme 1. Synthesis of piperazine based phthalimides.
the aid of COSY experiment. The IR spectra of phthal-
imides (3a-t) exhibited two characteristic stretching
bands (∼1714 cm−1 and ∼1650 cm−1) attributed to the
isoindoline ring and amide carbonyls, respectively.
3.2 Biological experiments
3.2a Apoptotic activity, morphological changes indu-
ced by various arylpiperazine based phthalimides and
their structure-activity relationship: All the listed
phthalimides (3a-t) were screened for in vitro apoptotic
assessment against testicular germ cells of goat (Capra
hircus) using histological and molecular (TUNEL
assay and fluorescence assay) techniques. The cell
degenerating efficiency of new phthalimides is summa-
rized in Table 1.
Five phthalimides (3b, 3f, 3j, 3m & 3p) were iden-
tified as potential apoptotic inducers. In the control
group, the testicular tissue sections were stained with
hematoxylin and eosin, which revealed the normal
arrangement of spermatogonia, spermatocytes, sper-
matids and sperms as shown in Figure 2A. In the exper-
imental group, the testicular tissue sections were treated
with 3 of the most promising phthalimides (3b, 3j &
3m) at the concentration of 10 μM. This resulted in
atretic changes viz., hyalinization, margination of chro-
matin material, pinching off of the nuclear material,
pyknotic nuclei, crescent-shaped nuclei, chromolysis,
Table 1. The percentage of apoptotic cell death induced by phthalimides
against testicular germ cells (model: Capra hircus). The testicular tissues were
incubated with phthalimides (10 μM in DMSO) for 6 h at 38◦C.
Entry R n R1 % Yield Atretic germ cells (%)
3a CH2CH(CH3)2 1 Br 82 51.33 ± 5.03
3b CH2C6H5 1 Br 72 64.67 ± 5.13
3c CH(CH3)2 1 Br 62 46.33 ± 4.50
3d CH3CHCH2CH3 1 Br 69 48.67 ± 4.72
3e CH2CH(CH3)2 1 F 68 43.33 ± 4.04
3f CH2C6H5 1 F 65 64.00 ± 3.00
3g CH(CH3)2 1 F 85 39.00 ± 5.00
3h CH3CHCH2CH3 1 F 69 45.33 ± 3.21
3i CH2CH(CH3)2 1 CF3 71 53.33 ± 4.04
3j CH2C6H5 1 CF3 72 68.67 ± 5.50
3k CH(CH3)2 1 CF3 63 48.00 ± 4.58
3l CH3CHCH2CH3 1 CF3 59 43.00 ± 5.56
3m CH2CH(CH3)2 1 C(CH3)3 75 66.67 ± 4.50
3n CH2C6H5 1 C(CH3)3 71 59.67 ± 3.05
3o CH(CH3)2 1 C(CH3)3 68 42.00 ± 5.13
3p CH3CHCH2CH3 1 C(CH3)3 80 62.67 ± 4.04
3q CH2CH(CH3)2 2 H 80 48.67 ± 3.51
3r CH2C6H5 2 H 72 61.33 ± 4.50
3s CH(CH3)2 2 H 61 41.33 ± 5.50
3t CH3CHCH2CH3 2 H 67 45.67 ± 6.11
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Figure 2. A) Photomicrograph of testicular tissue showing the normal
arrangement of spermatogonia, spermatocytes, spermatids and sperms in the
control group; B) Testicular tissue treated with phthalimide 3b showing dark
pyknotic nuclei (p) chromatin margination (arrow) and vacuolization (v); C)
Testicular tissues treated with 3j showing the degenerating changes such as
chromolysis (ch) nuclear condensation, crescent-shaped nuclei (arrow) and
increased vacuolization (v); D) Testicular tissue treated with 3m showing a
large number of atretic changes in the germ cells such as pyknotic nuclei (p)
and vacuolization (v) H &E (×1000).
vacuolization and fragmentation of nuclei, etc., as
shown in Figure 2B-D.
In 3’ end labelling, the cells with single small densely
stained nucleus were frequently observed (Figure 3B).
The appearance of cells with fragmented and margi-
nated chromatin material in the nucleus was noticed as
shown in Figure 3C. Also, the cells with multiple small
dark brown nuclear fragments were also frequently
seen (Figure 3D). The fluorescent microscopy of testi-
cular germ cells (control group) revealed pinkish nor-
mal germ cells with their intact cell membranes and
round nuclei (Figure 4A). However, the testicular germ
cells upon treatment with phthalimides (3b, 3j and 3m)
showed apoptotic effect with bright green condensed
nuclei (Figure 4B–D).
Based on the results of apoptotic activity of phthalim-
ides, the structure-activity relationship was described.
The isoindoline ring was kept common, whereas sub-
stituents on C-2 and fourth position of piperazine
were varied. From the apoptotic activity summarized
in Table 1, it is evident that most of the phthalimides
possessing benzyl ring on C-2 position proved to be
of higher potential than those having isobutyl, sec-
butyl, and isopropyl substituents. This advocates the
hydrophobic binding pocket around C-2 position. All
the compounds possessing isopropyl ring at C-2 posi-
tion showed the least apoptotic activity. The substi-
tution of trifluoromethyl group (3j) with a t-butyl
group (3n) retaining benzyl group at the C-2 posi-
tion, decreases the potency, suggesting a space lim-
ited but hydrophilic pocket around the fourth position
of piperazine ring. Substitution of fluorine (3j) with
bromine (3b) does not make any significant differ-
ence. The potency in the context of positional iso-
mers was also quite interesting. Phthalimide 3m is a
positional isomer of 3p and showed an almost similar
rate of activity i.e. percentage of atretic cells ∼66 and
∼62%, respectively. Similarly, 3a and 3d are the posi-
tional isomers and can degenerate ∼51 and ∼49% tes-
ticular germ cells, respectively. The apoptotic efficacy
in context to the substituents on C-2 position attains
the order viz. benzyl > isobutyl > sec-butyl > iso-
propyl. Among all phthalimides, 3j possessing benzyl
substituent at the C-2 position and the 4-trifluorobenzyl
substituent at the fourth position of piperazine was iden-
tified as the most potent apoptotic inducer and may be
a strong contender for the future development of cancer
chemotherapy.
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Figure 3. A) Photomicrograph of TUNEL stained testicular germ cells show-
ing light stained normal germ cells with their intact cell membrane in con-
trol group (arrow) ×1000; B) TUNEL stained apoptotic testicular germ cells
treated with Compound 3j showing single small densely stained nucleus having
pyknotic appearance (arrow) ×1000; C) stained testicular germ cells treated
with compound 3m showing apoptotic germ cell with nuclei containing the
condensed and marginated chromatin (arrow) ×1000; D) TUNEL stained tes-
ticular germ cells with 3b showing cells with multiple small nuclear fragments
and crescent shaped nucleus (arrow) ×1000.
3.2b Cellular oxidative stress study: The testicular
germ cells were treated with the most potent phthalim-
ide (3j), homogenised and assayed for cellular oxida-
tive stress by estimation of lipid peroxidation level
and Catalase, Glutathione-S-transferase (GST),55 and
Superoxide dismutase (SOD) activities. The treatment
of germ cells with most active phthalimide 3j resulted
in an immediate rise in the lipid peroxidation level. The
effect became pronounced and significant (p < 0.01)
in the cells treated with the treatment with 10–20 μM
of 3j (Figure 5A). The antioxidant enzymes viz, Cata-
lase, GST, and SOD isolated from treated cells (2 μM to
20 μM of 3j) showed significantly (p < 0.01) decline in
their activities (Figure 5B, C, D). The results obtained
from 10 and 20 μM concentration of 3j were compara-
ble (not significantly different) among them. This study
suggests that 10 μM dose of 3j is enough to induce
redox imbalance in the germ cells.
3.2c Activation of JNK and p53 observed in apoptotic
germ cells: The treatment of phthalimide 3j to germ
cells not only induces the activation of the intrinsic
pathway but also other pathways of apoptotic induction
like JNK and p53. Western blot analysis of mitogen-
activated protein (MAP) kinases, c-jun-N-terminal
kinase (JNK), its downstream target c-Jun (which is a
transcription factor, act as a pro-apoptotic factor) and
their phosphorylated forms showed a rise in the expres-
sion/phosphorylation as compared to the untreated con-
trols (Figure 6A–C). This advocated the crucial role of
JNK and c-Jun in the apoptotic induction of 3j. The
expression level was observed optimal when cells were
treated with 10–20 μM concentration of phthalimide 3j.
Tumour suppressor, p53 protein expression was seen as
upregulated in all treatment groups irrespective of the
treatment dose (Figure 6A–C). These results revealed a
significant role of JNK and p53 in apoptotic induction.
3.2d Molecular mechanism of germ cell apoptosis:
Phthalimide induces apoptosis via intrinsic pathway:
The study of the activation of caspases leading to pro-
grammed cell death could provide mechanistic informa-
tion regarding the available anticancer drugs. A number
of caspases are involved in the process of apoptosis
as mentioned earlier. However, caspase 9 which is an
important mediator of the intrinsic or mitochondrial
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Figure 4. A) Fluorescent photograph of testicular germ cells showing pink-
ish normal germ cells with intact cell membrane and round nuclei in control
group (arrow) ×400; B) Testicular germ cells supplemented with 3b showing
increase in number of apoptotic germ cells (arrow) ×400; C) Fluorescent pho-
tograph of testicular germ cells supplemented with 3j showing apoptotic germ
cell with a comet-like appearance (arrow) ×400; D) Testicular germ cells sup-
plemented with 3m showing a large number of apoptotic germ cells with bright
green condensed nuclei ×400.
Figure 5. Plate showing the redox imbalance in testicular germ cells upon the treat-
ment of 2–20 μM of 3j. A) Lipid peroxidation level by estimating TBRAS levels;
B) catalase activity; C) Glutathione-S-Transferase activity; D) Superoxide Dismutase
level.
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Figure 6. Protein expression analysis by Western Blots showing the expressions of A) JNK and pJNK: its
downstream target; B) c-Jun and p-c-Jun and C) the tumor suppressor protein p53.
pathway of apoptosis, and caspase 3 are considered as
crucial enzymes for programmed cell death. The treat-
ment of 3j showed a significant rise in the apoptotic
induction of germ cells. The redox status inside the cell
is important for correct functioning of several enzymes,
and can be used to alter enzyme activity. Thus, the alter-
ation of redox status could act as a signaling mech-
anism. It may either trigger or block the apoptotic
cell death programme depending on the severity of the
oxidative stress. Similarly, apoptosis has been observed
to be associated with a rise in oxidative stress depicted
by an increase in lipid peroxidation and decline in
cellular activity of Catalase, GST and SOD.14 This is
quite similar to the apoptotic response of germ cells
induced by H2O2. In the present study, caspases were
identified as important participants in the apoptotic
induction of testicular germ cells. Based on the results,
the intrinsic pathway involving caspase 9 and 3 was
recognised to be responsible for the activity. It was rec-
ognized that p53 induced apoptosis results from cel-
lular redox alterations. The redox alterations with ele-
vated oxidative stress induced genotoxic stress and this
genotoxic stress might affect p53 tumor suppressor
gene/protein. Moreover, p53 represents the sensor of
Figure 7. Graph showing caspase activities of treated germ cells with 2–20 μM concentration of 3j. A)
Caspase 8; B) Caspase 9; C) Caspase 3.
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DNA damage whose activation provides an opportunity
to repair any cellular damage prior to commitment to
undergo apoptosis.56
We studied changes in the caspase protein and
mRNA expression and their activities in induced germ
cells. The activity of caspase 9 and 3 was found to
be significantly (p < 0.01) elevated in the treated cells
(Figure 7B, C). Caspase 9 protein and its mRNA expres-
sion were also found upregulated which supports the
intrinsic/mitochondrial pathway of apoptosis in the tes-
ticular germ cells treated with 3j (Figure 8A, B). The
activity of caspase 8, protein expression coincided well
with the static and insignificant levels (p > 0.05) of their
specific transcripts, which indicated that the course of
signal transduction is not through extrinsic/death recep-
tor pathway (Figure 8A). The treatment of 3j to germ
cells have also induced an increase in the cleavage of
the DNA repair protein poly-ADP-ribose polymerase
(PARP) along with the increased activity of caspase 9
and 3 (Figure 8A). In the enzymatic analysis, the treat-
ment of 10 and 20 μM concentration of 3j to germ cells
afforded comparable results, not being significantly dif-
ferent with respect to each other. These findings clearly
indicated that phthalimide 3j is induced the oxidative
stress by unbalancing the cellular redox status caused
by cellular membrane lipid peroxidation and diminish-
ing the antioxidant enzyme activities. The change in
the redox status altered the mitochondrial permeabil-
ity and activating caspase 9, which in-turn activated
caspase-3. This resulted in the degradation of the repair
protein PARP and finally led to apoptosis. Besides,
MAP kinases were also observed to be activated pri-
marily by cytokines or exposure to the extracellular
stress including H2O2 or any other inducer like modified
phthalimide 3j. Based on our studies, the mediators of
stress viz. JNK and p38 MAPKs were found as impor-
tant for inducing the signals, and oxidative stress could
be responsible for the activation of MAPKs, which
ultimately leads to apoptosis.
Interestingly, the results of the current investigation
are comparable with the recent reports of piperazine
derivatives as apoptotic inducers.23,24
3.2e Effect of the most promising phthalimides
regarding apoptosis on the in vitro viability of cancer
cell lines: After verifying that phthalimides had an
apoptotic action in testicular germ cells, their cytotoxic
effect over cancer cells in culture was also evaluated.
For these assays, the best five phthalimides regarding
apoptotic action (3b, 3f, 3j, 3m & 3p) were chosen,
together with CAL-72 (from a human sarcoma) and
MCF-7 (from a human breast cancer) cell lines. The
cells were cultured in the presence of compound in con-
centrations ranging from 1 μM to 100 μM. Cytotoxicity
was indirectly determined by measuring the metabolic
activity of cells using the resazurin reduction assay. The
cytotoxicity behaviour of the five compounds is sum-
marized in Figure 9, Figure 10 and Table 2. The results
showed that the five compounds had similar behaviour
in both cells lines and allowed their classification into
3 groups: inactive (those compounds that do not show
activity in the range of concentrations tested; this was
the case of compound 3m having in the position C-
2 the t-butyl group), cytostatic (those compounds that
retard cell activity/multiplication in the range of con-
centrations tested; this was the case of compounds 3b,
3f and 3j having in the position C-2 the benzyl group)
and cytotoxic (those compounds that are toxic for cells;
this was the case of compound 3p having in the position
C-2 the sec-butyl group; compound 3p showed identical
IC50 values for both cell lines). Interestingly, although
all compounds were capable of inducing significant
apoptotic cell death in testicular germ cells when used
at the concentration of 10 μM, only compound 3p was
efficient in killing cancer cells in vitro.
3.3 Molecular Docking vs. Apoptotic Activity
The observations of enzymatic assays were validated
with the aid of molecular docking studies of phthalimide
3j with caspases. The docking studies were conducted
using Glide-XP protocol and the results are depicted
in Table S1 (see Supporting Information). The bind-
ing affinity estimates were calculated for 3j against
all seven caspase proteins. In comparison to other
Figure 8. Caspase 8 and 9 expression levels in testicular germ cells treated with 2–20 μM
concentration of 3j. A) Protein expression by Western blotting; B) Transcript levels by RT-PCR.
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Figure 9. Metabolic activity of CAL-72 cells exposed to different concentra-
tions of compounds 3b, 3f, 3j, 3m and 3p (percentage in relation to the con-
trol). The bars represent the standard deviation of the average value obtained
from 3 independent experiments.
Figure 10. Metabolic activity of MCF-7 cells exposed to different concen-
trations of compounds 3b, 3f, 3j, 3m and 3p (Percentage in relation to the con-
trol). The bars represent the standard deviation of the average value obtained
from 3 independent experiments.
Table 2. Effect of compounds 3b, 3f, 3j, 3m and 3p on the viability of CAL-72 and
MCF-7 cancer cell lines.
Compound CAL-72 MCF-7
3b Cytostatic Cytostatic
3f Cytostatic Cytostatic
3j Cytostatic Cytostatic
3m Inactive Inactive
3p Cytotoxic (IC50 = 70μM) Cytotoxic (IC50 = 68 μM)
caspases, ligand binding analyses with caspase 3
(3KJF) displayed a high Glide XP score of −4.32 kcal/mol
with binding free energy score (G), −67.71 kcal/mol.
Phthalimide 3j was observed to exhibit the close
contacts with residues -His121 and Trp206, which have
been proved experimentally as interacting sites for lig-
and binding in caspase 3 (Figure 11). We also observed
a significant G score, −66.13 kcal/mol for caspase
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Figure 11. Interaction diagram of phthalimide 3j and CASP3. A) A close-up view of 3j binding sites in CASP3 structure:
marked residues are mostly involved in the ligand interactions; B) 2D plot representation of the ligand-protein interaction
diagram: color represented different types of residues and bonding important for the interactions.
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9 (2AR9) and observed a couple of potential contacts
with phthalimide 3j (Figure 12). A significantly strong
protein-ligand interaction was observed between the
residue Arg355 and 3j. In addition, the residues
Trp354, Thr179, Arg180 and Thr181 also emerged as
important sites for ligand binding in caspase 9. We
observed a significant G score (−66.54 kcal/mol)
but a low glide score (−2.34 kcal/mol) for caspase 7
(4JR2) that indicated the poor contacts with 3j. Studies
revealed that caspase 2 and caspase 3 possess identical
residues at loop 4, which helps in the active receptor
binding mechanism.58,59
Figure 12. Interactions diagram for 3j ligand and CASP9. A) Highlighted residues in CASP9 struc-
ture formed close contact with 3j ligand during docking; B) 2D plot representation of the ligand-protein
interaction diagram: color represented different types of residues and bonding important for the interactions.
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Figure 13. A comparative view of dock poses for three different caspases. Interactions of 3j (ball-stick
conformation) in the active site of three different caspases (caspase 2, caspase 3 and caspase 6). The numbers
1 to 4 indicate the loops. The loop 4 regions are longer in caspase-2 and 3. The structures are in ribbon
representation and rainbow coloring.
A close interaction of many residues in the active
sites of caspase 3 was advocated by docking results
of caspase 2 and caspase 6 (Figure 13). Furthermore,
all the tautomers of 3j ligand showed a potentially
higher G score when docked against these three
proteins.
4. Conclusions
Apoptosis plays a significant role in the development
of normal cells and tissues. Apoptosis inducers are
considered as potential contenders for the development
of anticancer chemotherapeutics. The current study
presents a novel class of phthalimides functionalized
with arylpiperazines as significant inducers of apop-
tosis. The functionalization of arylpiperazines at the
para position was observed as a crucial step for the
significant apoptotic response. Phthalimide 3j possessing
benzyl substituent at the C-2 position and the 4-tri-
fluorobenzyl substituent at the fourth position of piperazine
was classified as a strong apoptotic inducer. The apoptotic
potency of new phthalimides was further confirmed
by TUNEL assay, fluorescence assay observing the
cleavage of DNA, caspase activities and various pro-
apoptotic protein/mRNA expression analyses. Our
study advocated phthalimide 3j as a significant inducer
for primary testicular germ cell apoptosis, and data
suggested that it may be a potential molecule in the
search for new therapeutic agents. The current studies
also demonstrated that structure-based design of these
new molecules is the crucial phase for the future
discovery of new anticancer agents. Further, clinicians
and R&D companies may extrapolate the phthalimide
system for the design of potent and efficient anticancerous
apoptotic agents, which might be beneficial to the
public health system.
Supplementary Information (SI)
All additional information relating to characterization
of the compounds such as 1H and 13C NMR spectra
(Figures S1–S40), 2-D NMR spectra (Figures S41–S43),
Images of CAL-72 and MCF-7 cells after incubation
of compound (Figure S44), Docking results of 3j lig-
and interacting with seven human caspases (Table TS1)
and Primer-specific conditions used for PCR ampli-
fication of candidate genes (Table TS2) are given in
the supporting information, available at www.ias.ac.in/
chemsci.
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